SIGA Technologies Inc

NASDAQ:SIGAUnited States

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The Company's lead product is TPOXX, also known as tecovirimat and ST-246, an orally administered and intravenous (IV) formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the United States maintains a supply of TPOXX under Project BioShield. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. It uses third parties known as contract manufacturing organizations to procure commercial raw materials and supplies, and to manufacture TPOXX.

Contact Information

Headquarters

31 East 62Nd StreetNEW YORK, NY, United States 10065

Phone

212-672-9100

Fax

212-697-3130

Executives

Chief Executive Officer, Director

Diem Nguyen

Chief Financial Officer, Executive Vice President, Corporate Secretary

Daniel Luckshire

Executive Vice President, Chief Scientific Officer

Dennis Hruby

General Counsel

Lawrence Miller

Director

Evan Knisely